RGNX · CIK 0001590877
What REGENXBIO Inc. told the SEC could break it.
What REGENXBIO flagged is a study in single points of failure. Almost all of its revenue — about 99% in 2025 — comes from royalties and license fees paid by just two partners, Novartis Gene Therapies and Nippon Shinyaku, so its top line effectively rides on those two relationships. The dependence runs through its operations too: it leans on sole-source suppliers for key components — one of them, Clearside, which supplies its SCS Microinjector, filed for bankruptcy in November 2025 — and on a single cGMP plant in Rockville, Maryland for production, all while carrying a $1.13 billion accumulated deficit and debt borrowed against its Zolgensma and Itvisma royalty streams.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- two licensees = ~99% of revenuehigh
Revenue is almost entirely license/royalty income from two customers — Novartis Gene Therapies and Nippon Shinyaku — who together accounted for ~99% of 2025 revenue.
“Two customers (Novartis Gene Therapies and Nippon Shinyaku) accounted for approximately 99% of our total revenues for the year ended December 31, 2025.”
SEC filing →As of 2026
Sole-source dependency
- sole-source suppliers incl. Clearside SCS Microinjector (Clearside bankruptcy Nov 2025)high
REGENXBIO relies on sole-source suppliers for key components, including the SCS Microinjector supplied by Clearside, which filed for bankruptcy in November 2025.
“We rely on third-party suppliers, including sole-source suppliers, for materials and key components used in our preclinical and clinical studies and for potential commercial use. Clearside supplies the SCS Microinjector under an option and license agreement; however, in November 2025, Clearside filed f”
SEC filing →As of 2026
Geographic concentration
- single cGMP manufacturing facility (RMIC, Rockville MD)medium
Commercial/clinical AAV production depends on a single cGMP facility, the RMIC, at the company's Rockville, Maryland headquarters.
“Our Good Manufacturing Practices (cGMP) production facility, the REGENXBIO Manufacturing Innovation Center (RMIC), is located in our corporate headquarters in Rockville, Maryland.”
SEC filing →As of 2026
Liquidity & debt
- $1.13B accumulated deficit; HCR royalty-backed debtmedium
REGENXBIO has a $1.13B accumulated deficit and has monetized/borrowed against Zolgensma and Itvisma royalties via HCR (up to $250M limited-recourse loan), creating dependence on those royalty streams.
“The Company has incurred cumulative losses since inception and as of December 31, 2025, had generated an accumulated deficit of $ 1.13 billion.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Nippon Shinyaku Co., Ltd.
“Two customers (Novartis Gene Therapies and Nippon Shinyaku) accounted for approximately 99% of our total revenues for the year ended December 31, 2025.”
Cited →“The Company and AbbVie will share equally in the net profits and net losses associated with the commercialization of ABBV-RGX-314 in the United States. Outside the United States, AbbVie will be responsible, at its sole cost, for the commercialization of ABBV-RGX-314.”
Cited →Novartis Gene Therapies (Novartis AG)
“Two customers (Novartis Gene Therapies and Nippon Shinyaku) accounted for approximately 99% of our total revenues for the year ended December 31, 2025.”
Cited →
Its suppliers
“Clearside supplies the SCS Microinjector under an option and license agreement; however, in November 2025, Clearside filed f”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch